Landmark FDA Approval for LYTENAVA™ Offers New Hope for Wet AMD Patients

Landmark FDA Approval for LYTENAVA™ Offers New Hope for Wet AMD Patients

In a significant development for the retinal disease community, Outlook Therapeutics, Inc. announced on July 24, 2026, that the U.S. Food and Drug Administration (FDA) has approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. This approval is particularly noteworthy as LYTENAVA™ is the first and only FDA-approved ophthalmic formulation of bevacizumab specifically developed for eye injections in the United States.

For decades, bevacizumab has been a widely utilized treatment in retina care, often used off-label through repackaged formulations originally intended for intravenous use. The approval of LYTENAVA™ fundamentally changes this landscape by providing retina specialists and patients with a purpose-built ophthalmic formulation designed specifically for intravitreal administration. This means the treatment now comes with validated manufacturing, approved labeling, comprehensive quality systems, and ongoing FDA regulatory oversight, addressing a long-standing need within the community.

LYTENAVA™ is a vascular endothelial growth factor (VEGF) inhibitor. It works by binding to VEGF-A, a protein that causes abnormal blood vessel growth and leakage in the eye, which contributes to vision loss in wet AMD. By inhibiting VEGF-A, LYTENAVA™ suppresses endothelial cell proliferation, neovascularization (new blood vessel formation), and vascular permeability, thereby helping to slow down vision loss. The recommended dosage is 1.25 mg (0.05 mL) administered as an intravitreal injection once a month, approximately every 28 days, by a qualified physician.

This approval is the culmination of a multi-year journey for Outlook Therapeutics, which included four Biologics License Application (BLA) submissions to the FDA. Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the U.S. before the end of 2026. The company anticipates that this approval will provide LYTENAVA™ with 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).

The introduction of an FDA-approved ophthalmic bevacizumab is a significant step forward, offering a new, regulated treatment option for individuals living with wet AMD. This development underscores the ongoing commitment within the biopharmaceutical industry to address unmet needs in retinal health and provides renewed hope for improved patient outcomes.